Diethylcarbamazine for lymphatic filariasis and tropical pulmonary eosinophilia


Ivermectin for onchocerciasis, lymphatic filariasis, scabies, strongyloidiasis, mansonelliasis, and malaria transmission


Albendazole for soil transmitted helminths (ascariasis, trichuriasis, and ancylostomiasis), lymphatic filariasis, oesophagostomiasis, and strongyloidiasis


Azithromycin for under-five mortality, trachoma, and yaws


The usual approach to mass drug administration is for tablets to be distributed from shared bottles without labels or instructions. As a result, patients have a lack of trust and effective coverage is poor. Because medicines in bottles are being supplied to governments and organizations at no cost, the makers are unwilling to change the packaging or otherwise improve products; they are also reluctant to allow products to leave their direct control to be blister-packaged elsewhere. The original donors of these medicines—EISAI, GSK, MSD, and Pfizer—have already been bearing the world’s treatment burden of these diseases for 35 years. Our blister-packaged generic tablets are attractive for both low- and middle-income countries. Right now, many countries can still access medicine donations in bottles, but as companies move to restrict their donations (either to areas with prevalence above a defined threshold or to low-income countries and away from middle-income countries), certain countries and organizations wish to procure their own medicines and prefer blister packaging.